S 288310/S 488310

Drug Profile

S 288310/S 488310

Alternative Names: Asudemotide; S-288310/S-488310; S-288310/S-488410; S-488310/S-288310; S-588410

Latest Information Update: 03 Aug 2016

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Shionogi
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Oesophageal cancer
  • Phase II Bladder cancer

Most Recent Events

  • 25 Jul 2016 Phase-I clinical trials in Oesophageal cancer (Neoadjuvant therapy) in Japan (SC) (UMIN000023324)
  • 26 Jan 2016 OncoTherapy Science plans a phase Ib trial for Mesothelioma
  • 09 Oct 2015 Shionogi completes enrolment in a phase II trial for Bladder cancer (Late-stage disease, Metastatic disease, Monotherapy) in Bulgaria, Japan and the UK (UMIN000013656)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top